The prognostic relevance of additional cytogenetic findings at diagnosis of chronic myeloid
leukemia (CML) is unclear. The impact of additional cytogenetic findings at diagnosis on …

Major route additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid
leukaemia (CML) indicate an increased risk of progression and shorter survival. Since major …

In the face of competing first-line treatment options for CML, early prediction of prognosis on
imatinib is desirable to assure favorable survival or otherwise consider the use of a second …

Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether
additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent …

Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic
myelogenous leukemia (CML) is generally associated with decreased response to tyrosine …

Chronic myeloid leukemia (CML) is the prototype cytogenetic malignancy. Even before the
development of basic G-and R-banding techniques, CML was found to be associated with a …

In chronic myeloid leukemia, different methods are available to monitor the response to
therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization …

Clonal chromosomal abnormalities in Philadelphia chromosome-negative (CCA/Ph−)
metaphases emerge as patients with chronic phase chronic myeloid leukemia (CP-CML) are …

The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …

The progress made in the understanding of chronic myeloid leukemia (CML) since the
recognition of a common chromosomal abnormality to the introduction of ever more effective …